Treatment outcomes with methylphenidate formulations among patients with ADHD: Retrospective claims analysis of a managed care population

Current Medical Research and Opinion

Volumn 27, Issue SUPPL. 2, 2011, Pages 53-62

  Hodgkins, Paul ^a   Sasané, Rahul ^a   Christensen, Laura ^b   Harley, Carolyn ^b   Liu, Fang ^b  

^a SHIRE   (United States)

^b OPTUM   (United States)

Author keywords

ADHD; Claims database; Managed care; Methylphenidate; Real world study; Treatment patterns

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CLONIDINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COMORBIDITY; DRUG DOSAGE FORM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; AGED; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DELAYED-ACTION PREPARATIONS; HUMANS; INSURANCE CLAIM REVIEW; MANAGED CARE PROGRAMS; MEDICATION ADHERENCE; METHYLPHENIDATE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 80053607875     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.623158     Document Type: Article

References (43)

1. Manos MJ. Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes. Medscape J Med 2008;8:10:5
2. Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:71-8 (Pubitemid 32592007)
3. Kessler R, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23 (Pubitemid 44464584)
4. Hodgkins P, Montejano L Sasané R, et al. Risk of injury associated with attention-deficit/hyperactivity disorder in adults enrolled in employer-sponsored health plans. Primary Care Companion 2011;13:e1-e12
5. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003;2:104-13
6. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005;366:237-48 (Pubitemid 40981053)
7. Purper-Ouakil D, Cortese S, Wohl M, et al. Predictors of diagnostic delay in a clinical sample of French children with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2007;16:505-9
8. Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a populationbased study. J Dev Behav Pediatr 2006;27:1-10 (Pubitemid 44315107)
9. Powers RL, Marks DJ, Miller CJ, et al. Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic achievement. J Child Adolesc Psychopharmacol 2008;18:449-59
10. Scheffler RM, Brown TT, Fulton BD, et al. Positive association between attention-deficit/hyperactivity disorder medication use and academic achievement during elementary school. Pediatrics 2009;123:1273-9
11. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-age child with attention-deficit/hyperactivity disorder. Pediatrics 2001;4:1033-44
12. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance [CADDRA]. Canadian ADHD Practice Guidelines. Available at: http://www.caddra.ca/ cms4/index.php?optioncom-content&viewarticle&id 26&Itemid353& langen [Last accessed November 2009]
13. Kendall T, Taylor E, Perez A, et al. Diagnosis and management of attentiondeficit/hyperactivity disorder in children, young people, adults: summary of NICE guidance. BMJ 2008;337:a1239
14. Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-21
15. Brown RT, Amler RW, Freeman WS, et al.; American Academy of Pediatrics Committee on Quality Improvement. American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder. Treatment of attention-deficit/ hyperactivity disorder: overview of the evidence. Pediatrics 2005;115:e749-e757 (Pubitemid 43843150)
16. Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:501-10
17. Jair R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011;50:171-9
18. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry 2010;19:83-105
19. Weiss MD, Gadow K, Wasdell MB, et al. Effectiveness outcomes in attentiondeficit/hyperactivity disorder. J Clin Psychiatry 2006;67(Suppl 8):38-45
20. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70(Suppl 4):1-46
21. Buckstein OG. Satisfaction with treatment for attention-deficit/ hyperactivity disorder. Am J Manag Care 2004;10:S107-16
22. Buckstein OG, Arnold LE, Landgraf JM, et al. Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child Adolesc Psych Mental Health 2009;2:39
23. Frazier TW, Weiss M, Hodgkins P, et al. Time course and predictors of healthrelated quality of life improvement and medication satisfaction in children diagnosed with attention-deficit/hyperactivity disorder treatment with the methylphenidate transdermal system. J Child Adolesc Psychopharmacol 2010;20:355-64
24. Manos M, Frazier TW, Landgraf JM, et al. HRQL and medication satisfaction in children with ADHD treatment with the methylphenidate transdermal system. CMRO 2009;25:3001-10
25. Weiss MD, Gibbins C, Goodman DW, et al. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder. J Clin Psych 2010;71:381-90
26. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder. NICE clinical guideline 72. NICE, 2008. Available at: http://guidance.nice.org.uk/CG72/NICEGuidance/pdf/English [Last accessed 22 Sep 2011]
27. Preuss U, Ralston SJ, Baldursson G, et al. ADORE Study Group. Study design, baseline patient characteristics and intervention in a cross-cultural framework: results from the ADORE study. Eur Child Adolesc Psychiatry 2006;15(Suppl 1):14-14
28. Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol 2007;32:711-27 (Pubitemid 47356048)
29. Christensen L, Sasané R, Hodgkins P, et al. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 2010;26:977-89
30. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997;19:1446-57 (Pubitemid 28133280)
31. Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder. A systematic, placebo-controlled evaluation. Paediatrics 1990;86:184-92 (Pubitemid 20238848)
32. Swanson JM, Gupta S, Williams L, et al. Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry 2002;41:1306-14 (Pubitemid 38338021)
33. Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder-first upgrade. Eur Child Adolesc Psychiatry 2004;13(Suppl 1):17-30
34. Olfson M, Marcus S, Wan G. Stimulant dosing for children with ADHD: a medical claims analysis. J Am Acad Child Adolesc Psychiatry 2009; 48:51-9
35. Vitiello B, Severe JB, Greenhill LL, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry 2001;40:188-96 (Pubitemid 32111022)
36. Vitiello B, Abikoff HB, Chuang SZ, et al. Effectiveness of methylphenidate in the 10-month continuation phase of the preschoolers with attention-deficit/hyperactivity disorder treatment study (PATS). J Child Adolesc Psychopharmcol 2007;17:593-604
37. Perwein AR, Hall J, Swensen A, et al. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/ hyperactivity disorder. JMCP 2004;10:122-9
38. Pappadopulos E, Jensen PS, Chait AR, et al. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry 2009;48:501-10
39. Sanchez RJ, Crismon ML, Barner JC, et al. Assessment of adherence measures with difference stimulants among children and adolescents. Pharmacotherapy 2005;25:909-17 (Pubitemid 40917923)
40. Meijer WE, Bouvy ML, Heerdink ER, et al. Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors. Br J Psychiatry 2001;179:519-22 (Pubitemid 34031677)
41. Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-22 (Pubitemid 30082525)
42. Arnold LE. Methylphenidate vs. amphetamine: comparative review. J Attention Disord 2000;4:200-11
43. Faraone SV, Short EJ, Biederman J, et al. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study. Int J Neuropsychopharmacol 2002;5:121-9 (Pubitemid 34662974)